3rd Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$630,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Generic drug quality and FDA oversight Part D Formulary Design and Generic Drug Tiering Electronic Labeling of Prescription Drugs H.R. 1319 - American Rescue Plan Act FDA facility inspections Medicare incentives for biosimilar utilization H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act FY2022 Labor, HHS, Education, and Related Agencies Appropriations Bill Generic Drug User Fee Amendments (GDUFA) Complex Generic Drug Approvals H.R. 3 - Lower Drug Costs Now Act H.R. 2846 - Ensuring Access to Lower-Cost Medicines for Seniors Act Biosimilar interchangeability

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Bills named: H.R. 2846 (117th), H.R. 1319 (117th), H.R. 4356 (117th), H.R. 3 (117th)

Trade (domestic/foreign) TRD

Trade issues related to generic medicines Pharmaceutical supply chain

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —

Contacted: Commerce, Dept of (DOC); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Financial Institutions/Investments/Securities FIN

Policy related to corporate governance

LobbyistCovered position, as disclosed
DAVID MARIN —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); SENATE; Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC)

Taxation/Internal Revenue Code TAX

Corporate Tax Policy

LobbyistCovered position, as disclosed
AKSHAI DATTA —
DAVID MARIN —
PETER WALLACE —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); SENATE; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC)

Copyright/Patent/Trademark CPT

Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs Patent Settlements

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Budget/Appropriations BUD

Medicaid Rebate provision of the Bipartisan Budget Act of 2015

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: Commerce, Dept of (DOC); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.